In the past two week, the U.S. FDA has awarded three new RMAT designations, bringing the total number of awards to 19.
The new RMAT designations were awarded to:
- Nightstar Therapeutics: Gene therapy (NSR-REP1) for choroideremia treatment – June 14, 2018
- Caladrius Biosciences: CD34+ cell therapy (CLBS14) for refractory angina – June 19, 2018
- Voyager Therapeutics: Gene therapy (VY-AADC ) for Parkinson’s disease – June 22, 2018